3 Strong Oncology & Specialty Momentum: Beyond neuroscience, BMSs growth portfolio delivered $6.9B, led by: OPDIVO (nivolumab) US HCP: $2.5B (+8%) Breyanzi (lisocabtagene maraleucel) HCP: $359M (+58%) CAMZYOS (mavacamten) US HCP: $296M (+88%) These results reinforce BMSs transformation into a data-rich, diversified biopharma, with pivotal readouts expected in 2026 across fibrosis, multiple myeloma, and autoimmune indications
, Me 12 Me 12
Time your orders around when you know you will be home
Full therapeutic benefit typically becomes evident within three to six months, with many patients experiencing sustained pain relief that persists long after the treatment course ends
Semaglutide can reduce B12 absorption by slowing gastric emptying and altering the stomach environment
The Copper Peptide Uglies: What They Are and Why They Happen If you have spent any time in skincare forums, you have encountered the phrase "copper peptide uglies." It sounds dramatic because, for the people who experience it, it feels dramatic